Platelet Indices Analyzed for Tuberculosis and Diabetes Mellitus Co-Morbidity
|
By LabMedica International staff writers Posted on 03 Jun 2021 |

Image: The Mindray BC-6800 hematology analyzer (Photo courtesy of Shenzhen Mindray Bio-Medical Electronics)
Studies have demonstrated that some diseases accelerate Tuberculosis (TB) occurrence and development. Type 2 diabetes mellitus (DM) has been verified as one of the threatening risk factors for TB, and patients have three times the risk of developing TB compared to non-diabetic patients due to pathogenic mechanisms and metabolic factors.
Platelets are enucleate cells and have critical roles in thrombosis, homeostasis and the inflammatory response. When the internal environment is changed, platelet morphology may be altered and play a role in certain platelet-associated parameters, mainly including platelet count (PC), plateletcrit (PCT), platelet distribution width (PDW) and mean platelet volume (MPV).
Clinical Laboratorians at Nantong University College of Medicine (Nantong, China) enrolled in a study 246 patients admitted to the hospital and were distributed into three groups (113 TB, 59 DM and 74 TB + DM). A total of 133 individuals were also recruited as healthy controls (HC). Platelet indices, namely, platelet count (PC), mean platelet volume (MPV), plateletcrit (PCT) and platelet distribution width (PDW), were compared among the four groups, and the relationship with inflammatory markers was explored by using statistical software.
TB diagnose was based on positive results of Xpert MTB/RIF (Cepheid Inc., Sunnyvale, CA, USA). The team used BACTEC MGIT 960 rapid liquid isolate culture (Becton Dickinson, Sparks, MD, USA), and the GenoType check system (Hain Lifescience, Nehren, Germany), and MTB smear confirmation by Ziehl-Neelsen acid-fast stain. Full blood counts were carried out using Mindray BC-6800 hematology analyzer (Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Shenzhen, China). The Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were also measured.
The scientists reported that MPV and PCT were significantly downregulated in TB + DM patients (9.95 ± 1.25 fL, 0.20 ± 0.05%, separately) compared with DM individuals (10.92 ± 1.17 fL, 0.22 ± 0.04%). Moreover, the changes in MPV were significantly higher in TB + DM patients (9.95 ± 1.25 fL) than in TB patients (9.42 ± 1.01 fL). MPV improved the diagnosis sensitivity when it was combined with clinical parameters, such as fasting blood glucose in DM and Mycobacterium tuberculosis culture result in TB (76.3% versus 64.9%, 72.6% versus 60.8%), respectively. In addition, the sensitivity and specificity of PCT in the differential diagnosis of DM patients versus TB + DM patients were 69.5 and 59.4%, respectively. PCT improved the diagnosis sensitivity when combined with fasting blood glucose in DM (72.9% versus 64.9%). In addition, MPV was linked to CRP and ESR in the TB + DM patients.
The authors concluded that MPV is a valuable candidate marker to screen for TB-DM coinfection risk, as the occurrence of TB developing into TB-DM coinfection will increase MPV levels, and DM developing into a DM-TB coinfection will decrease MPV levels. MPV has significant specificity and sensitivity for predicting and diagnosing DM-TB coinfection. The study was published on May 20, 2021 in the journal BMC Infectious Diseases.
Related Links:
Nantong University College of Medicine
Cepheid Inc
Becton Dickinson
Hain Lifescience
Shenzhen Mindray
Platelets are enucleate cells and have critical roles in thrombosis, homeostasis and the inflammatory response. When the internal environment is changed, platelet morphology may be altered and play a role in certain platelet-associated parameters, mainly including platelet count (PC), plateletcrit (PCT), platelet distribution width (PDW) and mean platelet volume (MPV).
Clinical Laboratorians at Nantong University College of Medicine (Nantong, China) enrolled in a study 246 patients admitted to the hospital and were distributed into three groups (113 TB, 59 DM and 74 TB + DM). A total of 133 individuals were also recruited as healthy controls (HC). Platelet indices, namely, platelet count (PC), mean platelet volume (MPV), plateletcrit (PCT) and platelet distribution width (PDW), were compared among the four groups, and the relationship with inflammatory markers was explored by using statistical software.
TB diagnose was based on positive results of Xpert MTB/RIF (Cepheid Inc., Sunnyvale, CA, USA). The team used BACTEC MGIT 960 rapid liquid isolate culture (Becton Dickinson, Sparks, MD, USA), and the GenoType check system (Hain Lifescience, Nehren, Germany), and MTB smear confirmation by Ziehl-Neelsen acid-fast stain. Full blood counts were carried out using Mindray BC-6800 hematology analyzer (Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Shenzhen, China). The Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were also measured.
The scientists reported that MPV and PCT were significantly downregulated in TB + DM patients (9.95 ± 1.25 fL, 0.20 ± 0.05%, separately) compared with DM individuals (10.92 ± 1.17 fL, 0.22 ± 0.04%). Moreover, the changes in MPV were significantly higher in TB + DM patients (9.95 ± 1.25 fL) than in TB patients (9.42 ± 1.01 fL). MPV improved the diagnosis sensitivity when it was combined with clinical parameters, such as fasting blood glucose in DM and Mycobacterium tuberculosis culture result in TB (76.3% versus 64.9%, 72.6% versus 60.8%), respectively. In addition, the sensitivity and specificity of PCT in the differential diagnosis of DM patients versus TB + DM patients were 69.5 and 59.4%, respectively. PCT improved the diagnosis sensitivity when combined with fasting blood glucose in DM (72.9% versus 64.9%). In addition, MPV was linked to CRP and ESR in the TB + DM patients.
The authors concluded that MPV is a valuable candidate marker to screen for TB-DM coinfection risk, as the occurrence of TB developing into TB-DM coinfection will increase MPV levels, and DM developing into a DM-TB coinfection will decrease MPV levels. MPV has significant specificity and sensitivity for predicting and diagnosing DM-TB coinfection. The study was published on May 20, 2021 in the journal BMC Infectious Diseases.
Related Links:
Nantong University College of Medicine
Cepheid Inc
Becton Dickinson
Hain Lifescience
Shenzhen Mindray
Latest Clinical Chem. News
- Saliva-Based Test Detects Biochemical Signs of Sleep Loss
- Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
- Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
- Urine-Based Test Shows Promise for Autism Screening in Children
- Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s
- Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
- Urine-Based Alzheimer’s Test Receives FDA Breakthrough Device Designation
- Fluid Biomarker Improves Diagnosis and Monitoring of Primary CNS Lymphoma
- New CA19-9 Cutoff Value Helps Identify High-Risk Pancreatic Cancer Patients
- Blood-Based Biomarkers Show Promise for Psychosis Risk Prediction
- International Experts Recommend Ending Routine 'Corrected' Calcium Reporting
- Long-Term Data Show PSA Screening Modestly Reduces Prostate Cancer Deaths
- Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively
- FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing
- CE-Marked Blood Biomarker Test Advances Automated Alzheimer’s Diagnostics
- Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
Rapid identification of Ebola infections is essential to limit transmission and guide public health response, yet detection can be difficult when outbreaks involve rare variants. The current outbreaks... Read more
Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
Lung cancer remains a leading cause of cancer death, and many cases are detected only after symptoms appear. Current screening programs largely target people with a history of smoking, leaving other at-risk... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more








